We subsequently performed the same experiment using the AA patient‐derived RC77T prostate cancer cell line, and the results were essentially the same (Fig. 4D–F, Fig. S4), underscoring that although a molecular phenotype may be enriched in PCa from AAM (i.e., TP53 wild‐type, IL‐6 derived from the environment), it is not exclusive to PCa from AAM. This evidence concerns the gene TP53 and prostate cancer.